AP2241A - Pyrimidine derivatives for the treatment of abnormal cell growth. - Google Patents
Pyrimidine derivatives for the treatment of abnormal cell growth.Info
- Publication number
- AP2241A AP2241A AP2006003790A AP2006003790A AP2241A AP 2241 A AP2241 A AP 2241A AP 2006003790 A AP2006003790 A AP 2006003790A AP 2006003790 A AP2006003790 A AP 2006003790A AP 2241 A AP2241 A AP 2241A
- Authority
- AP
- ARIPO
- Prior art keywords
- treatment
- cell growth
- abnormal cell
- pyrimidine derivatives
- pyrimidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57131204P | 2004-05-14 | 2004-05-14 | |
| PCT/IB2005/001201 WO2005111023A1 (en) | 2004-05-14 | 2005-05-02 | Pyrimidine derivatives for the treatment of abnormal cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AP2006003790A0 AP2006003790A0 (en) | 2006-10-31 |
| AP2241A true AP2241A (en) | 2011-06-01 |
Family
ID=34966230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AP2006003790A AP2241A (en) | 2004-05-14 | 2005-05-02 | Pyrimidine derivatives for the treatment of abnormal cell growth. |
Country Status (27)
| Country | Link |
|---|---|
| EP (1) | EP1751143A1 (en) |
| JP (1) | JP4099212B2 (en) |
| KR (1) | KR100886990B1 (en) |
| CN (2) | CN1953974A (en) |
| AP (1) | AP2241A (en) |
| AR (1) | AR049097A1 (en) |
| AU (2) | AU2005243397A1 (en) |
| BR (1) | BRPI0511138A (en) |
| CA (1) | CA2566707A1 (en) |
| CR (1) | CR8749A (en) |
| EA (1) | EA200601796A1 (en) |
| EC (1) | ECSP066997A (en) |
| GE (1) | GEP20104875B (en) |
| GT (1) | GT200500113A (en) |
| IL (1) | IL178828A0 (en) |
| MA (1) | MA28583B1 (en) |
| MX (1) | MXPA06011890A (en) |
| NL (2) | NL1029045C2 (en) |
| NO (1) | NO20064576L (en) |
| NZ (1) | NZ550448A (en) |
| PA (1) | PA8632601A1 (en) |
| PE (1) | PE20060240A1 (en) |
| TN (1) | TNSN06370A1 (en) |
| TW (1) | TWI303635B (en) |
| UY (1) | UY28894A1 (en) |
| WO (1) | WO2005111023A1 (en) |
| ZA (1) | ZA200608394B (en) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4812763B2 (en) * | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | Cycloalkyl-substituted pyrimidinediamine compounds and uses thereof |
| US20070032514A1 (en) * | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| CA2634646C (en) * | 2005-12-21 | 2012-04-10 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GEP20125581B (en) * | 2007-04-18 | 2012-07-25 | Pfizer Prod Inc | Sulfonyl amide derivatives for treatment of abnormal cell growth |
| WO2009012421A1 (en) * | 2007-07-17 | 2009-01-22 | Rigel Pharmaceuticals, Inc. | Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
| US8461147B2 (en) * | 2007-12-03 | 2013-06-11 | Boehringer Ingelheim International Gmbh | Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| LT2300013T (en) * | 2008-05-21 | 2017-12-27 | Ariad Pharmaceuticals, Inc. | Phosphorous derivatives as kinase inhibitors |
| US8410126B2 (en) * | 2009-05-29 | 2013-04-02 | Boehringer Ingelheim International Gmbh | Pyrimidine inhibitors of PKTK2 |
| JP5539518B2 (en) | 2009-08-14 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives |
| US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| JPWO2014174745A1 (en) * | 2013-04-26 | 2017-02-23 | 国立大学法人京都大学 | Eg5 inhibitor |
| CN109608444B (en) * | 2018-11-27 | 2022-02-11 | 中国药科大学 | Isoindolinone-containing ERK inhibitor and preparation method and application thereof |
| CN111732548B (en) * | 2020-06-11 | 2022-06-17 | 浙江大学 | N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2004056807A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9721437D0 (en) * | 1997-10-10 | 1997-12-10 | Glaxo Group Ltd | Heteroaromatic compounds and their use in medicine |
| AR042586A1 (en) | 2001-02-15 | 2005-06-29 | Sugen Inc | 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE |
| UA80767C2 (en) * | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
-
2005
- 2005-05-02 KR KR1020067023767A patent/KR100886990B1/en active IP Right Grant
- 2005-05-02 MX MXPA06011890A patent/MXPA06011890A/en unknown
- 2005-05-02 CN CNA2005800155302A patent/CN1953974A/en active Pending
- 2005-05-02 AU AU2005243397A patent/AU2005243397A1/en not_active Abandoned
- 2005-05-02 CN CN2011100212904A patent/CN102127058A/en active Pending
- 2005-05-02 EA EA200601796A patent/EA200601796A1/en unknown
- 2005-05-02 EP EP05732043A patent/EP1751143A1/en not_active Withdrawn
- 2005-05-02 BR BRPI0511138-2A patent/BRPI0511138A/en not_active IP Right Cessation
- 2005-05-02 WO PCT/IB2005/001201 patent/WO2005111023A1/en active Application Filing
- 2005-05-02 GE GEAP20059703A patent/GEP20104875B/en unknown
- 2005-05-02 NZ NZ550448A patent/NZ550448A/en unknown
- 2005-05-02 AP AP2006003790A patent/AP2241A/en active
- 2005-05-02 CA CA002566707A patent/CA2566707A1/en not_active Abandoned
- 2005-05-02 JP JP2007512557A patent/JP4099212B2/en active Active
- 2005-05-11 PA PA20058632601A patent/PA8632601A1/en unknown
- 2005-05-11 TW TW094115237A patent/TWI303635B/en active
- 2005-05-12 PE PE2005000534A patent/PE20060240A1/en not_active Application Discontinuation
- 2005-05-12 UY UY28894A patent/UY28894A1/en not_active Application Discontinuation
- 2005-05-13 GT GT200500113A patent/GT200500113A/en unknown
- 2005-05-13 NL NL1029045A patent/NL1029045C2/en active Search and Examination
- 2005-05-13 AR ARP050101969A patent/AR049097A1/en not_active Application Discontinuation
-
2006
- 2006-05-19 NL NL1031845A patent/NL1031845C2/en active Search and Examination
- 2006-10-06 ZA ZA200608394A patent/ZA200608394B/en unknown
- 2006-10-09 NO NO20064576A patent/NO20064576L/en not_active Application Discontinuation
- 2006-10-23 IL IL178828A patent/IL178828A0/en unknown
- 2006-11-13 EC EC2006006997A patent/ECSP066997A/en unknown
- 2006-11-13 CR CR8749A patent/CR8749A/en not_active Application Discontinuation
- 2006-11-13 TN TNP2006000370A patent/TNSN06370A1/en unknown
- 2006-11-14 MA MA29452A patent/MA28583B1/en unknown
-
2009
- 2009-11-13 AU AU2009238255A patent/AU2009238255A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003030909A1 (en) * | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| WO2004056807A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Pyrimidine derivatives for the treatment of abnormal cell growth |
Non-Patent Citations (1)
| Title |
|---|
| C. T. SUPURAN; A. SCOZZAFAVA: "Protein kinase inhibitors as anticancer agents" EXPERT OPIN. THER. PATENTS, vol. 14, no. 1, January 2004 (2004-01), pages 35-53 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AP2241A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth. | |
| IL191555A0 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| AP2385A (en) | Pyrimidine derivatives for the treatment of abnormal cell growth. | |
| AU2003288603A8 (en) | Pyrimidine derivates for the treatment of abnormal cell growth | |
| IL232511A0 (en) | Sulfonyl amide derivatives for the treatment of abnormal cell growth | |
| AP2378A (en) | Sulfonamide derivatives for the treatment of diseases. | |
| AP2359A (en) | Sulfonamide derivatives for the treatment of diseases. | |
| IL183706A0 (en) | 2,4(4,6) pyrimidine derivatives | |
| IL177232A0 (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| PL1784399T3 (en) | Pyrimidine derivatives | |
| EG25081A (en) | Use of prolines for improving growth and/or yield. | |
| WO2006124713A3 (en) | 4-biarylyl-1-phenylazetidin-2-ones | |
| HK1118556A1 (en) | 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives | |
| IL161908A0 (en) | Quinazoline derivatives for the treatment of abnormal cell growth | |
| HK1104553A1 (en) | Pyrimidine derivatives | |
| NO20053483D0 (en) | 4-Anilinoquinazoline derivatives for the treatment of abnormal cell growth | |
| EP1924717A4 (en) | Methods for enhancing the dewaterability of sludge with alpha-amylase treatment | |
| EG25401A (en) | Process for the preparation of urea. | |
| EP1750698A4 (en) | 5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes | |
| ZA200608015B (en) | Heteroarylaminopyrazole derivatives useful for the treatment of diabetes | |
| GB0421359D0 (en) | Method for the inactivation of enzymes | |
| PL375287A1 (en) | New derivative of isoxazol [4,5-d] pyrimidine and method for the manufacture of the new derivative of isoxazol [4,5-d] pyrimidine | |
| IL179092A0 (en) | Spiroderivatives for the treatment of hypertension |